Ask The Doctor: December 2021
Caregivers come to our home to help with my wife, who has dementia. Because we…
Category: dementia
Gifts That Cushion, Comfort, and Assist
Everyone can use a helping hand every now and then. And that’s especially true if…
.jpg)
STAT+: European regulators signal Biogen’s new Alzheimer’s therapy is unlikely to win approval
A panel of European drug reviewers notified Biogen that its Alzheimer’s treatment Aduhelm is unlikely…
STAT+: In a sudden move, Al Sandrock, the man behind Biogen’s Aduhelm, to retire
Al Sandrock, Biogen’s top scientist and the face of its years-long campaign to develop a…
STAT+: Cortexyme bets a lower dose of its once-failed Alzheimer’s drug can work in another trial
Cortexyme, pressing forward after its novel approach to Alzheimer’s disease failed in a mid-stage trial,…
STAT+: Scientists find a clue to why some people have ‘Alzheimer’s brains’ but no dementia
Defective proteins clump into toxic plaques and tangles. Plaques of amyloid and tau tangles kill…
STAT+: The loudest physician proponents of Aduhelm have all taken money from Biogen
WASHINGTON — A small group of physicians with deep, at times undisclosed, financial ties to…
Newsbites: Activity and cardiovascular health; produce and cognitive health; caution with vitamin E and beta-carotene
Metabolically Healthy Obesity” May Not Protect Against Heart Disease If you are obese but all…
STAT+: Cortexyme’s bacteria-fighting Alzheimer’s drug fails primary goal, but company sees a path forward
A novel approach to treating Alzheimer’s disease failed to preserve memory and function in a…
STAT+: Pharmalittle: FDA panel to review Pfizer Covid shot for kids; Novartis may sell or spin off its Sandoz generic unit
Good morning, everyone, and how are you today? A spot of rain, and then some,…
Type 3 Diabetes: Does Diabetes Cause Memory Loss?
Type 2 diabetes is diabetes that you are not born with. It develops over time….
Athira chief executive resigns as company confirms she altered research
The chief executive of biotech Athira Pharma has permanently left the company after papers she…
Listen: Inside the vaccine race, how a Covid pill failed, & Biogen’s troubled launch
Is Moderna misunderstood? Can Biogen turn a profit in Alzheimer’s disease? And what went wrong…
STAT+: Biogen’s Aduhelm sales fall dramatically below Wall Street’s expectations
Biogen made just $300,000 from the Alzheimer’s disease treatment Aduhelm in the first full quarter…
Irisin May Have a Future as Treatment to Reduce Brain Inflammation, Preserve Memory
The protective benefits of regular exercise on cognition are well established, but researchers are still…
How to Retrieve “Lost” Memories
While certain memories seem to be locked in place and unforgettable, there are plenty of…
.jpg)
Mouse experiments with a decades-old drug suggest a new approach to Alzheimer’s treatment
A generic drug used widely to treat swelling associated with hypertension and heart failure showed…
Listen: An Alzheimer’s scholar on the paradox of declining dementia rates
Although billions of dollars have been poured into potential pharmaceutical cures for dementia, particularly Alzheimer’s…
Insomnia Can Be Especially Harmful to Older Adults
Tossing and turning throughout the night, difficulty falling asleep, and nonrestorative sleep are all hallmarks…
Inflammaging: Connecting Aging and Chronic Diseases
Geroscience is a growing discipline that seeks to understand the relationship between aging and age-related…
EN on Foods: Egg-ceptional Eggplant!
The Folklore. The eggplant, also called aubergine, brinjal, and guinea squash, is known for its…
STAT+: Biogen, Eisai seek fast approval for second Alzheimer’s drug, relying on relaxed FDA standard
Biogen and its Japanese partner Eisai announced Monday evening the start of an application process…
Aspiration Pneumonia: Causes, Symptoms & Treatment
When you inhale fluid or food into your lungs, it is called aspiration. The fluid…
Listen: Scott Gottlieb on the next pandemic, another Covid winter, & Aduhelm’s slow rollout
What does Covid-19 have in store for this winter? Is Aduhelm a commercial dud? And…
Opinion: The brain health paradox: Dementia rates have fallen even as drugs have failed
Billions of dollars have been spent in pursuit of a pharmaceutical treatment for Alzheimer’s and…
STAT+: Biogen’s Aduhelm sales slower than disclosed, forcing company to consider cost-cutting measures
Earlier this month, Biogen executives admitted publicly that the launch of Aduhelm, its treatment for…
Frontline: Hot flashes; Dementia; Enjoyable way to improve health
Dietary Changes Curb Hot Flashes for Some Women Adding soybeans and removing animal-sourced foods from…
Listen: Verily’s moment of truth, Aduhelm’s rocky rollout, & the problem with Covid testing
Are we ever getting that Tricorder? Why’s it so hard to find Covid-19 tests? And…
Congress demands documents from FDA on controversial approval of Biogen’s Alzheimer’s drug
WASHINGTON — Lawmakers have requested data and documents from the Food and Drug Administration related…
How to Differentiate Between Signs of Normal Aging and Dementia
It’s not surprising that people worry about getting Alzheimer’s disease or another form of dementia…
Ask the Doctor: September 2021
Q. I have seen ads for smartphone apps that offer mental health counseling. Is it…
Ask the Doctor: September 2021
Q. What does the new Alzheimer’s disease drug do, who is it for, and why…
Sleep Apnea Solutions Using CPAP Alternatives
Obstructive sleep apnea is a common condition that can increase your risk for a lot…
STAT+: Discovery of rare mutation in a brain protein adds fuel to debate over cause of Alzheimer’s disease
In 2014, two siblings came to see Lena Kilander about some of the problems they’d…
STAT+: Will controversy over new Alzheimer’s drug spell the end for the FDA’s faster approval process?
WASHINGTON — For most of its history, the Food and Drug Administration’s shortcut pathway for…
Listen: The mRNA gold rush, Delta’s alarming rise, & the next treatment for Alzheimer’s
Who’s going to win the mRNA bake-off? How worrisome is the Delta variant? And why…
STAT+: Federal watchdog will review the controversial FDA approval of Biogen’s Alzheimer’s drug
The federal watchdog at the Department of Health and Human Services will review the process…
Alzheimer’s patients are in limbo as hospitals, insurers grapple with whether to offer Aduhelm
For all the explosive controversy over the approval of the first treatment for Alzheimer’s disease…
STAT+: Alzheimer’s scientists critique Cassava Sciences’ study results — overblown, inappropriate, uninterpretable
Independent researchers are expressing doubts about the purported benefits of an experimental treatment for Alzheimer’s…
STAT+: Here’s why simply approving Aduhelm can’t guarantee a golden age of Alzheimer’s R&D
Since the controversial approval of the Alzheimer’s drug Aduhelm, both the Food and Drug Administration…
What happened to the FDA’s toughest regulator?
You’re reading the web edition of D.C. Diagnosis, STAT’s weekly newsletter about the politics and…
STAT+: How Biogen found a believer: At the FDA, a hard-nosed regulator was won over on controversial Alzheimer’s drug
When the drug maker Biogen pitched its Alzheimer’s treatment to a panel of independent experts…
Ask the Experts: Moving to Memory Care; Heart Transplantation in Seniors; Bloating from Fiber
I’ve been caring for my elderly mother for a couple of years, but her dementia…
Be Careful With Central Nervous System Medications
Like the population at large, it’s not unusual for people with dementia to also experience…
Biogen mounts defense of its Alzheimer’s drug, saying ‘misinformation’ is fueling controversy
Biogen on Thursday mounted a vigorous defense of its controversial Alzheimer’s drug, Aduhelm, with the…
STAT+: Accelerated approval, the path used to greenlight Biogen Alzheimer’s drug, has a checkered track record, critics say
If ever there were a cautionary tale for the Food and Drug Administration’s approval of…
Listen: The FDA’s future, Biden’s tight ship, & the latest Aduhelm twist
Who’s going to run the FDA? Why isn’t the Biden administration leakier? And what if…
STAT+: The ins and outs of the rare, controversial way Medicare might pay for Biogen’s new Alzheimer’s drug
WASHINGTON — The Food and Drug Administration last month foisted a nearly impossible decision on…
FDA chief Janet Woodcock acknowledges agency may have misstepped in process leading up to Alzheimer’s drug approval
WASHINGTON — Acting Food and Drug Administration Commissioner Janet Woodcock acknowledged on Wednesday her agency…
STAT+: ‘’This is unprecedented’: Several private insurers won’t cover Biogen’s Alzheimer’s drug
At least half-a-dozen private health insurers in some of the nation’s largest states are balking…